M&A Deal Summary

AMAG Pharmaceuticals Acquires Cord Blood Registry

On August 17, 2015, AMAG Pharmaceuticals acquired healthcare services company Cord Blood Registry from GTCR for 700M USD

Acquisition Highlights
  • This is AMAG Pharmaceuticals’ 1st transaction in the Healthcare Services sector.
  • This is AMAG Pharmaceuticals’ largest (disclosed) transaction.
  • This is AMAG Pharmaceuticals’ 2nd transaction in the United States.
  • This is AMAG Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary

Date 2015-08-17
Target Cord Blood Registry
Sector Healthcare Services
Buyer(s) AMAG Pharmaceuticals
Sellers(s) GTCR
Deal Type Add-on Acquisition
Deal Value 700M USD
Advisor(s) Houlihan Lokey (Financial)
Kirkland & Ellis (Legal)

Target

Cord Blood Registry

San Bruno, California, United States
CBR Systems is a late-stage medical devices company with the leading market position in providing the collection, processing and cryogenically-frozen storage of stem cells.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AMAG Pharmaceuticals

Waltham, Massachusetts, United States

Category Company
Founded 1981
Sector Life Science
Employees440
Revenue 328M USD (2019)
DESCRIPTION

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse. AMAG Pharmaceuticals was formed in 1981 and is based in Waltham, Massachusetts.


DEAL STATS #
Overall 2 of 3
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 2 of 3
State (California) 1 of 1
Country (United States) 2 of 3
Year (2015) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-09-29 Lumara Health

St. Louis, Montana, United States

Lumara Health, Inc. is a pharmaceutical company committed to advancing the health of women throughout the stages of their lives, with a particular focus on maternal health.

Buy $675M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-13 Perosphere Pharmaceuticals

Danbury, Connecticut, United States

Perosphere Pharmaceuticals, Inc. is a private clinical-stage company focused on developing rescue drugs. Perosphere Pharma's lead investigational drug product candidate, ciraparantag (PER977), is an FDA Fast Track designated, intravenously administered small synthetic water-soluble new molecular entity intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and low molecular weight heparin.

Buy -

Seller(S) 1

SELLER

GTCR

Chicago, Illinois, United States

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 1980
PE ASSETS 15.0B USD
Size Mega
Type Sector Agnostic
DESCRIPTION

GTCR is a private equity firm that typically partners with management when pursuing acquisitions. The Firm looks to grow companies through build-on acquisitions, consolidations, and internal growth. GTCR will consider both equity and mezzanine capital commitments and concentrates its investment activity in consumer products & services, healthcare services, outsourced business services, technology, transaction processing, and pharma/medical products. GTCR was formed in 1980 and is based in Chicago, Illinois.


DEAL STATS #
Overall 52 of 84
Sector (Healthcare Services) 11 of 16
Type (Add-on Acquisition) 28 of 40
State (California) 3 of 8
Country (United States) 50 of 81
Year (2015) 5 of 9
Size (of disclosed) 19 of 33
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-27 Capella Healthcare

Franklin, Tennessee, United States

Capella Healthcare is a provider of healthcare services. Capella Healthcare is based in Franklin, Tennessee.

Sell $900M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-01 Aligned Asset Managers

Stamford, Connecticut, United States

Aligned Asset Managers, headquartered in Stamford, CT, is a financial services holding company that specializes in making substantial equity investments in traditional and alternative investment firms.

Sell -